Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study.
V J Felitti, R F Anda, D Nordenberg...
https://pubmed.ncbi.nlm.nih.gov/9635069/Actively Recruiting
Led by University of Iowa · Updated on 2025-11-24
300
Participants Needed
1
Research Sites
21 weeks
Total Duration
Adverse childhood experiences ACEs, such as abuse and neglect during the first 18 years of life, are linked to a higher risk of cardiovascular diseases and death. This research investigates how mitochondrial dysfunction may contribute to impaired blood vessel function in young adults with a history of ACEs. The study aims to understand the biological causes of these vascular problems to help develop ways to reduce cardiovascular risks in affected individuals. Participants will receive either a single dose of a mitochondrial-targeted antioxidant supplement called Mitoquinone Mesylate MitoQ or a placebo. Before and after taking the supplement, blood vessel function will be measured using a special test called flow mediated dilation. Participants will then undergo a standardized psychosocial stress test while researchers collect blood samples and monitor vascular and stress responses to see if reducing mitochondrial oxidative stress improves these functions. During the study, participants will visit the lab to provide blood samples and undergo vascular function tests before and after supplementation. They will also be monitored during and after the stress test through blood pressure measurements, blood samples, and other cardiovascular assessments. The primary outcomes include changes in vascular function, blood pressure, endothelial cell microparticles, and cortisol levels, with additional measures of cardiac output and growth factors. The study will help identify how mitochondrial stress affects cardiovascular health in young adults with ACEs.
CONDITIONS
Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adversity
M
Manoela Lima Oliveria, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Iowa
Lead Sponsor
MitoQ Limited
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | MitoQ (investigational) | Placebo (trial comparator) |
|---|---|---|
| What this option is | An investigational mitochondria‑targeted antioxidant supplement (MitoQ) taken as a single 160 mg oral dose | A matching placebo containing microcrystalline cellulose and tapioca taken as a single 160 mg oral dose |
| Role in the trial | Participants receive this to test its effect on vascular and stress‑response outcomes | Participants receive this as a control to compare against the investigational MitoQ |
| Primary use or purpose | To evaluate whether acute MitoQ supplementation improves vascular endothelial function and stress‑related cardiovascular responses in young adults with early life adversity | To serve as a control for assessing the specific effects of MitoQ under study conditions |
| Administration | Single 160 mg oral dose given in capsule form with water | Single oral dose matching MitoQ in capsule form with placebo ingredients |
| Evidence beyond this trial | Some evidence in non‑trial studies shows MitoQ may acutely improve flow‑mediated dilation in adults with lower baseline endothelial function | Placebo is inactive control, no therapeutic effect |
| Important risks | Risk profile uncertain—safety not established for 160 mg single dose in this population | Placebo is inactive and expected to carry no risk beyond capsule ingestion |
| Important limitations | Evidence is limited to acute single‑dose use in a specialized young population with early life adversity; broader effectiveness unknown | As an inert comparator, does not test active benefit—only useful for comparison within trial |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants consume a single acute dose of either the mitochondrial targeted antioxidant supplement (MitoQ) or placebo. Vascular endothelial function and blood samples are collected before and after supplementation, followed by a standardized psychosocial stress test with additional blood sampling.
1 visit (in-person)
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
V J Felitti, R F Anda, D Nordenberg...
https://pubmed.ncbi.nlm.nih.gov/9635069/Shaoyong Su, Marcia P Jimenez, Cole T F Roberts...
https://pubmed.ncbi.nlm.nih.gov/26289252/Nathaniel D M Jenkins, Emily M Rogers, Nile F Banks...
https://pubmed.ncbi.nlm.nih.gov/34328346/University of Iowa
Lead Sponsor
MitoQ Limited
Collaborating Sponsor